Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00182507
• Date of registration: 14/09/2005
• Primary sponsor: Hamilton Health Sciences Corporation
• Public title: Olanzapine in the Treatment of Hair Pulling (Trichotillomania)
• Scientific title: A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania
• Date of first enrolment: June 2000
• Target sample size: 34
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00182507
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Countries of recruitment

Canada

Contacts

• Name: Michael A Van Ameringen, MD, FRCPC
• Affiliation: Hamilton Health Science, McMaster Univeristy Medical Centre

Key inclusion & exclusion criteria

Inclusion Criteria:

- primary DSM-IV trichotillomania; CGI-Severity = 4

Exclusion Criteria:

- Any other Axis I primary diagnosis; CGI-S < 4; current comorbid: OCD, MDD, alcohol or
substance abuse; lifetime hx of: schizophrenia, bipolar affective disorder or
dementia; current pregnancy/lactation; current suicidality or homicidality; major
medical problems or clinically unstable medical disease; hx of: seizures, stroke or
head trauma; prior use of neuroleptics



Age minimum: 18 Years
Age maximum: 65 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Trichotillomania

Intervention(s)

Drug: Olanzapine

Primary Outcome(s)

Clinical Global Impression (CGI)-Improvement Scale = 2

Secondary Outcome(s)

CGI-Severity Scale, Mean change from baseline in: Yale-Brown Obsessive Compulsive Scale for TTM, the Massachusetts General Hospital Hair Pulling Scale

Secondary ID(s)

00-167

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Eli Lilly and Company